Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 18/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18508396 | 0.83 | CYP11B2 (0.64) | CYP11B2 | |
| SCHEMBL17207675 | 0.83 | CYP11B2 (0.64) | CYP11B2 | |
| SCHEMBL18502913 | 0.79 | CYP11B2 (0.47) | CYP11B2 | |
| SCHEMBL17207637 | 0.72 | CYP11B2 (0.65) | CYP11B2 | |
| SCHEMBL18502895 | 0.71 | CYP11B2 (0.68) | CYP11B2 | |
| SCHEMBL17207562 | 0.71 | CYP11B2 (0.72) | CYP11B2 | |
| SCHEMBL3392361 | 0.70 | PARP1 (0.40) | CYP11B2ALDH1A1MAP4K1 | |
| SCHEMBL18489958 | 0.70 | CYP11B2 (0.73) | CYP11B2ALDH1A1 | |
| SCHEMBL17207657 | 0.69 | CYP11B2 (0.73) | CYP11B2 | |
| SCHEMBL17207661 | 0.68 | CYP11B2 (0.66) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| WO-2015163427-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | 田辺三菱製薬株式会社 | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | NR3C2, REN, CYP21A2 | CYP11B2 17/4885ALDH1A1 80/4885MAP4K1 1681/4885 |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | CYP11B2 19/4885ALDH1A1 68/4885MAP4K1 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.